




Contents lists available at ScienceDirect

Schizophrenia Research: Cognition

journal homepage: www.elsevier.com/locate/scog

Neuroinflammation and kynurenines in schizophrenia: Impact on cognition depending on cognitive functioning and modulatory properties in relation to cognitive remediation and aerobic exercise

Jacopo Sapienza^{a,b,*}, Giulia Agostoni^a, Stefano Comai^{c,e,f,g}, Sofia Nasini^c, Stefano Dall'Acqua^c, Stefania Sut^c, Marco Spangaro^a, Francesca Martini^a, Margherita Bechi^a, Mariachiara Buonocore^a, Giorgia Bigai^d, Federica Repaci^a, Daniela Nocera^d, Chiara Ave^d, Carmelo Guglielmino^a, Federica Cocchi^a, Roberto Cavallaro^{a,d}, Giacomo Deste^{h,i}, Marta Bosia^{a,d}

^a Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy

^b Department of Humanities and Life Sciences, University School for Advanced Studies IUSS, Pavia, Italy

^c Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy

^d School of Medicine, Vita-Salute San Raffaele University, Milan, Italy

^e Division of Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy

^f Department of Psychiatry, McGill University, Montreal, QC, Canada

^g Department of Biomedical Sciences, University of Padua, Padua, Italy

^h Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

ⁱ Department of Mental Health and Addiction Services, ASST Valcamonica, Esine, Italy

ARTICLE INFO

Keywords:

Cognition

Kynurenine pathway

Interleukines

Non-pharmacological treatments

TNF- α

Kynurenine 3-monooxygenase

ABSTRACT

Background: In the last decade, the kynurenine pathway (KP) has gained attention in the pathogenesis of cognitive impairment in schizophrenia being at the crossroad between neuroinflammation and glutamatergic and cholinergic neurotransmission. However, clinical findings are scarce and conflicting, and the specific contributions of these two systems to the neurobiology of cognitive symptoms are far from being elucidated. Furthermore, little is known about the molecular underpinnings of non-pharmacological interventions for cognitive improvement, including rehabilitation strategies.

Methods: The current study examined 72 patients with schizophrenia, divided in two clusters depending on the severity of the cognitive impairment, with the aim to evaluate the impact of inflammatory biomarkers and KP metabolites depending on cognitive functioning. Moreover, we studied their possible link to the cognitive outcome in relation to sessions of cognitive remediation therapy (CRT) and aerobic exercise (AE) in a longitudinal arm of 42 patients.

Results: Neuroinflammation appeared to exert a more pronounced influence on cognition in patients exhibiting a higher cognitive functioning, contrasting with the activation of the KP, which had a greater impact on individuals with a lower cognitive profile. Cognitive improvements after the treatments were negatively predicted by levels of TNF- α and positively predicted by the 3-hydroxykynurenine (3-HK)/kynurenine (KYN) ratio, an index of the kynurenine-3-monooxygenase (KMO) enzyme activity.

Conclusion: Overall, these findings add novel evidence on the biological underpinnings of cognitive impairment in schizophrenia pointing at a differential role of neuroinflammation and KP metabolites in inducing cognitive deficits depending on the cognitive reserve and predicting outcomes after rehabilitation.

* Corresponding author at: Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy.

E-mail address: sapienza.jacopo@hsr.it (J. Sapienza).

<https://doi.org/10.1016/j.scog.2024.100328>

Received 27 October 2023; Received in revised form 26 August 2024; Accepted 26 August 2024

Available online 29 August 2024

2215-0013/© 2024 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Schizophrenia is a severe mental illness characterized by high heterogeneity in terms of symptoms, biological underpinnings and clinical course (Tandon et al., 2009; Bosia et al., 2022). Cognitive impairments continue to pose a significant challenge in schizophrenia as its underlying neurobiology is multifaceted, encompassing complex interactions between several molecules which might help to explain the heterogeneity of cognitive profiles (Bechi et al., 2019; Harvey et al., 2022; Sapienza et al., 2023b).

1.1. Cognitive impairment and neurotransmission: the role of the kynurenine pathway

The dopaminergic system was the first to be investigated with regards to cognition, and several pieces of evidence pointed at frontal and pre-frontal dopamine levels as one of the crucial determinants of the cognitive outcome (Braver et al., 1999; Bosia et al., 2007). Other robust findings were then reported on the relationship between *N*-methyl-D-aspartate (NMDA) neurotransmission and the cholinergic system and cognitive functioning (Spangaro et al., 2012; Moghaddam and Javitt, 2012). Indeed, it was observed that compounds which stimulate cholinergic receptors improve cognitive performances (Gibbons and Dean, 2016). Differently, molecules that block NMDA receptors cause cognitive impairment (Verma and Moghaddam, 1996; Moghaddam et al., 1997). However the glutamatergic system still remains an open issue, as glutamatergic neurotransmission improve the cognitive functioning but at the same time high levels of glutamate can induce excitotoxicity, which causes loss of neurons and damage to oligodendrocytes, thus white matter (WM) disruption (Wang and Qin, 2010; Domercq et al., 2005; Matute et al., 2007).

Notably, the kynurenine (KYN) pathway (KP) of tryptophan (Trp) is of interest in schizophrenia being at the crossroad between neuroinflammation and neurotransmission, as two of the main enzymes of the pathway, the indolamine-2,3-dioxygenases 1 and 2 (IDO1 and IDO2), are induced by pro-inflammatory cytokines (Comai et al., 2020; Messaoud et al., 2022), and some downstream metabolites can modulate cholinergic and glutamatergic neurotransmission (Sapienza et al., 2024b). IDO1, IDO2 and tryptophan-2,3-dioxygenase (TDO) convert Trp into KYN which is then metabolized either by the kynurenine aminotransferase (KATs) enzymes into kynurenic acid (KYNA) or by the kynurenine 3-monooxygenase (KMO) enzyme into 3-hydroxykynurenine (3-HK) (Comai et al., 2020). 3-HK showed neurotoxic properties in several studies, however some findings on its neuroprotective effect are also described (Colín-González et al., 2013). 3-HK can be transformed either in xanthurenic acid (XA) by KATs or to 3-hydroxyanthranilic acid (3-HANA) by the enzyme kynureninase. 3-HANA, following some enzymatic and nonenzymatic steps is then converted into either picolinic acid or quinolinic acid (QUIN) which spontaneously converts into nicotinic acid, an intermediate in NAD⁺ synthesis (Comai et al., 2020). During inflammatory conditions, cytokines can increase the amount of Trp catabolised along the KP inducing an unbalance between neuroactive, neurotoxic and neuroprotective metabolites depending on the activity of specific enzymes of the pathway (Comai et al., 2020; Kindler et al., 2020). Overall, it is important to note that both neuroinflammation and KP metabolites can impact cognitive function (Kindler et al., 2020; Sapienza et al., 2023b).

1.2. Cognitive impairment and the role of the immune system

Besides neurotransmitter dysregulation impacting cognition in schizophrenia, the role of neuroinflammation in cognitive impairment is gaining attention (Khandaker et al., 2015; Kindler et al., 2020; North et al., 2021; Patlola et al., 2023). Indeed, several studies identified the activation of microglia and increased levels of pro-inflammatory cytokines as pivotal pathogenic mechanisms of the disease (van Berckel

et al., 2008; Howes and McCutcheon, 2017). The cytokines which play a major role in the pathophysiology of schizophrenia are Interleukin (IL)-1 β , Tumor Necrosis Factor (TNF)- α , IL 6, IL-17, but also many other chemokines (Potvin et al., 2008; Miller et al., 2011). Notably, also systemic inflammation/sub-inflammation is able to impact cognition as widely reported by several studies on metabolic health in patients with schizophrenia that pointed out a crosstalk of the immune system between the brain and the periphery (Yaffe et al., 2004; Boyer et al., 2014; Bosia et al., 2021). Indeed, Metabolic Syndrome (MetS) is a frequent comorbidity of schizophrenia and it is associated to an increased peripheral levels of cytokines and chemokines due to insulin resistance, which cause the secretion of resistin by the adipose tissue, and dyslipidemia in a vicious circle (Strassnig et al., 2014; Grover et al., 2019; Cuoco et al., 2022). The systemic sub-inflammation and neuroinflammation trigger a wide range of cognitive deficits due to the induction of high oxidative stress, cytotoxicity, enhanced synaptic pruning due to microglia activation, and white matter (WM) disruption (Howes and McCutcheon, 2017; Uptegrove and Khandaker, 2020; North et al., 2021; Sapienza et al., 2023a; Patlola et al., 2023; Howes and Onwordi, 2023; Sapienza et al., 2024a).

1.3. Cognitive remediation and aerobic exercise

Cognitive Remediation therapy (CRT) is a behavioral training-based intervention mainly delivered through electronic devices, which is effective in improving and preventing cognitive decline in multiple cognitive domains, with persistent effects on both cognition and functional outcome even 10 years later (Cavallaro et al., 2009; Buonocore et al., 2022). It mainly induces molecular changes at central level (Spangaro et al., 2018; Penadés et al., 2018; Matsuda et al., 2019) and the most recent European guidelines for schizophrenia treatment identified CRT as the best option to improve cognition in schizophrenia despite the moderate effect size (Vita et al., 2022; Wykes et al., 2011). Therefore, other non-pharmacological treatments should be explored in augmentation to CRT to further improve cognition, and, given that the comorbidity with metabolic syndrome affects over 40 % of people with schizophrenia and it is proven to affect the degree of response to CRT, aerobic exercise (AE) has gained attention. Indeed, several meta-analyses demonstrated the efficacy of AE in improving global cognition, attention/vigilance, working memory, verbal learning, reasoning and problem solving in patients with schizophrenia (Firth et al., 2017; Shimada et al., 2022; Xu et al., 2022). Interestingly, it was demonstrated that AE is able to reduce systemic sub-inflammation, thus the peripheral activation of the KP which leads to accumulation of KP metabolites in the brain with possible positive implications for cognition (Cervenka et al., 2017; Martin et al., 2020).

1.4. Aims

The specific contribution of the kynurenine pathway (KP) and neuroinflammation to the observed cognitive impairment in schizophrenia remains unclear. Therefore, there is an urgent need to thoroughly investigate and unravel the biological foundations of cognitive impairment, considering the varying levels of cognitive functioning, as distinct performances may align with different molecular substrates (Kindler et al., 2020; Sapienza et al., 2023b). In this study, our primary objective was thus to investigate the relationship between inflammatory markers, kynurenine pathway (KP) metabolites, and cognitive performance in patients with schizophrenia, considering their cognitive profiles. The secondary aim was to examine the interplay between CRT, AE, and inflammatory/KP markers to identify reliable indicators of cognitive improvement associated with rehabilitative interventions. We hypothesized that a proinflammatory state and elevated levels of neurotoxic KP metabolites might impede cognitive improvement following interventions. Regarding neuroactive KP metabolites, their impact was anticipated to be contingent on their ability to either support or hinder

glutamatergic or cholinergic neurotransmission.

2. Materials and methods

2.1. Participants

The sample is derived from a multicenter Randomized Controlled Trial (RCT) including 93 patients, which took place from 2019 to 2023 at the Schizophrenia Research and Clinical Unit, IRCCS San Raffaele Scientific Institute of Milan and at the Department of Mental Health, Spedali Civili Hospital of Brescia. Patients were diagnosed with schizophrenia according to the DSM-5 criteria. The inclusion criteria were age between 18 and 65 years and diagnosis of schizophrenia according to the DSM-5 criteria. Exclusion criteria were hospitalization due to psychotic exacerbation, psychiatric and cardiac comorbidities, intellectual disability (IQ < 70), substance or alcohol abuse, neurological disorders and brain injury, concomitant infectious/inflammatory diseases or cancer. The sample consisted of patients in the chronic phase of the illness with no acute exacerbation requiring hospitalization or changes in antipsychotic treatment in the previous two months and through the duration of the study, with an overall mild to moderate severity of illness (symptom dimension detailed in 3.1). First-line responder patients were treated with haloperidol, risperidone or paliperidone, resistant patients (Treatment-Resistant Schizophrenia, TRS) were treated with clozapine as indicated for TRS (Zanardi et al., 2022), whereas ultra-treatment-resistant patients were treated with clozapine + one of the first line antipsychotics in augmentation.

2.2. Study design

After a complete description of the study protocol, informed consent to participation was obtained from 93 patients. The protocol followed the principles of the Declaration of Helsinki and was approved by the local ethics committee. Then, 60 patients were randomly assigned 1: 1: 1 to 3 treatment-arms: 1) 1 h CRT twice a week for 3 months; 2) 1 h-session of AE twice a week for 3 months, or 3) both CRT + AE. For this study, the analysis included a cross sectional sample of 72 patients and a longitudinal arm of 42 patients. Among the 60 patients who initially constituted the 3 longitudinal arms, only 16 patients in the CRT + AE group, 15 in the AE group and 11 in the CRT group completed the

program as shown in Fig. 1. In the longitudinal arm, cognitive functioning and psychopathology were assessed pre and post interventions while plasma levels of inflammatory and KP biomarkers were assessed at baseline. Details on the study protocol are shown in Fig. 1. Demographic, cognitive and clinical data of the longitudinal sample are reported in Table 2 and levels of biomarkers at baseline are reported in Table 3.

2.3. Cognitive assessment

The Italian version of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) was administered by trained psychologists and was used to assess 6 cognitive domains: Processing speed, Attention, Working memory, Verbal learning, Visual learning and Reasoning. Specifically, the Symbol Coding, the Animal Naming and the Trail Making tests were used to assess Processing speed. The Continuous Performance Test (CPT) and the Neuropsychological Assessment Battery were used to assess Attention and Reasoning respectively, whereas Working Memory was assessed through the Spatial Span and Letter-Number Span tests. Finally, the Hopkins Verbal Learning Test and the Brief Visuospatial Memory Test were used to estimate Verbal learning and Visual learning respectively (Nuechterlein et al., 2008).

2.4. Psychopathology

Psychopathology was assessed with the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) (Kay et al., 1987). The clinical interview and evaluation of symptoms were performed by trained psychiatrists. The total score and the scores of the three subscales (Positive Scale, Negative Scale, and General Psychopathology Scale) were then calculated.

2.5. Laboratory analysis

Blood was collected by venipuncture in Vacutainer tubes containing EDTA in the morning after a fasting overnight period, then centrifuged at 2000 ×g for 15 min at 4 °C, then plasma was divided into 200 µL small aliquots and stored at -80 °C. Plasma concentrations of immune analytes IL-1β, IL-6, IL-1ra, IL-9, IL-10, IL-13, IL-17A, Interferon (IFN)-γ, MIP1α, PDGF-BB, RANTES e TNF-α and ANP were determined using an Elisa kit according to manufacturer's instructions (Raybiotech, Atlanta, USA). Plasma levels of the main metabolites of the KP were measured following standard methodological procedures in the lab (Sapienza et al., 2024b) (Comai et al., 2022). The analysis of Trp and KYN was performed with a high performance liquid chromatography (HPLC) system coupled with a fluorometric detector for Trp and UV-Vis detector for KYN. 3-hydroxykynurenine (3-HK), KYNA and QUIN were determined using a LC-MS/MS Varian system composed of a binary Prostar pump, 410 autosampler, and MS320 triple quadrupole mass spectrometer equipped with Electro Spray ion source. The instrument worked in multiple reaction monitoring mode for all the molecules in positive ion mode, except for QUIN that was quantified in negative mode. The quantification of 3-HK, QUIN, and KYNA was calculated using alfa-methyl Trp as an internal standard. The following ratios were calculated as indirect index/proxy of the activity of the following enzymes of the KP: KYN/Trp of Indoleamine 2,3-dioxygenase (IDO), KYNA/KYN of KYN aminotransferase II, and 3-HK/KYN of kynurenine-3-monooxygenase.

2.6. Interventions

2.6.1. Cognitive remediation therapy

The CRT protocol consisted of two 1-h sessions per week of domain-specific computerized exercises, over a period of 3 months (12 weeks), for a total of 36 h. Computer-assisted neurocognitive exercises were




Fig. 1. Study design and flowchart.

performed using the Cogpack Software (Marker, 1987–2007) and the cognitive domains targeted by the CRT are those assessed by the MATRICS scale. Sets of exercises were individually created for each patient based on their performance at the baseline and then the program was set for adaptive exercises, based on subjects' performances during the session. Therefore, for each cognitive domain there are different types of exercises with different degrees of difficulty. For each poor performance (0–1 equivalent score), a domain-specific exercise was included, while, for each good performance (2–4 equivalent score), a non-domain-specific exercise was added. Exercises were administered by trained psychologists, and their role was to support the patients and motivate them during the execution of the CRT without providing the correct answer or solution to the exercises (see Cavallaro et al., 2009).

2.6.2. Aerobic exercise

AE consists of two 1-h sessions of AE per week for 3 months with cycle-ergometer for 40 min at 60 % of the maximum individual oxygen supply and heart rate. Patients performed also 10 min of stretching before and after AE. The choice of cycle-ergometer was made based on the poor feasibility to deliver other types of interventions (walking, jogging) in the hospital setting maintaining the training effect. Similarly, we decided to exclude interventions with a low training potential (low amount of burnt Kcal), such as tai chi, meditation or yoga.

2.6.3. Standard rehabilitation therapy

All patients also received a Standard Rehabilitation Therapy (SRT) consisting of 1-h sessions twice a week to ensure the same intensity and frequency in the three treatment arms. SRT included non-cognitive subprograms of Integrated Psychological Therapy (IPT) (Verbal Communication, Social Skill Training, and Problem-Solving) (Zimmer et al., 2007), social skills training programs for residential, vocational, and recreational functioning (Roder et al., 2002), and psychoeducational interventions (Bechdolf et al., 2004). The social skills training was based on role-playing methodology and selecting daily life activities according to patient needs, to reduce social anxiety, interrupt negative self-reinforcement and to increase social performance. The Problem-Solving module dealt with problem identification, cause-effect reasoning and effective social behavior. Psychoeducational sessions were devoted to the identification of symptoms, relapses and needs, as well as on the use of medication, treatment compliance and the management of side effects elicited by antipsychotics with the goal to increase patient knowledge regarding the illness and to improve treatment compliance.

2.6.4. Cognitive remediation therapy + aerobic exercise

Patients who underwent CRT + AE performed CRT right before or after the two weekly sessions of AE with the cycle-ergometer with a time-break of about 30 min. Therefore, both protocol treatments were applied in the same two days of attendance of our Unit.

2.7. Statistical analysis

Statistical analyses were performed with STATISTICA software package for Windows, version 8 and IBM SPSS statistics 27 (Chicago, IL). Figures were made with Rstudio. First, we performed partial correlations to address the relationship between the plasma levels of inflammatory markers, metabolites of the KP and the MCCB cognitive domains in the all sample constituted by 72 patients using age and sex as possible covariates. Then, to achieve a better understanding of the molecular underpinnings underlying cognitive functioning in schizophrenia we decided to split the sample in two subsamples of patients with a high or low cognitive profile. We thus performed a two-step cluster analysis, considering MATRICS scores of neurocognition as clustering variables and then, we re-explored correlations in the two subsamples. Based on these results, we performed multiple stepwise regressions to identify possible predictors of cognitive improvement after treatment, with the

$\Delta(T1-T0)$ of the MCCB scores as dependent variables, in order to identify the biomarkers of cognitive improvements after all the CRT, AE or CRT + AE interventions. No differences were made among the three interventions due to the relative small number of the longitudinal arm. For the same reason (restricted longitudinal arm), we decided to consider only the ratios as indexes of enzymes activity (KYN/Trp, KYNA/KYN and 3-HK/KYN ratios) and balance of neuromodulatory properties, while cytokines were selected on the basis of both evidence emerged in the literature and exploratory correlations. Indeed, there is evidence that cytokines can induce the kynurenine pathway (Pedrazz-Petrozzi et al., 2020). A two-tailed *p*-value <0.05 was considered statistically significant.

3. Results

3.1. Clinical and demographic characteristics of the sample

Demographic characteristics, symptomatology and cognitive performances at baseline and the mean dosage of chlorpromazine equivalents are reported in Table 1.

Table 1
Demographic, clinical characteristics and biomarkers of the whole sample.

Demographic characteristics	Mean (Standard Deviation)
Age	36.30 (12.60)
Education	11.21 (2.80)
Sex (M/F, % M)	75.26 % M
Onset	21.56 (4.82)
Duration of illness (years)	15.49 (11.37)
Chlorpromazine equivalents	448.51 (251.47)
PANSS	
PANSS Positive	18.69 (6.55)
PANSS Negative	21.91 (5.86)
PANSS General	40.40 (10.62)
PANSS Total	81.01 (19.14)
Matrics	
Processing Speed	32.62 (12.20)
Attention	36.22 (10.73)
Working Memory	37.80 (12.71)
Verbal Learning	41.60 (11.65)
Visual Learning	32.19 (10.90)
Reasoning	38.69 (10.10)
Biomarkers	
IL-1beta (pg/mL)	1.30 (1.70)
IL-1ra (pg/mL)	243.11 (222.47)
IL-6 (pg/mL)	5.22 (8.91)
IL-9 (pg/mL)	541.85 (69.39)
IL-10 (pg/mL)	3.99 (2.71)
IL-13 (pg/mL)	2.15 (1.72)
IL-17A (pg/mL)	6.53 (3.70)
IFN-gamma (pg/mL)	2.10 (1.30)
MIP-1alfa (pg/mL)	1.26 (0.46)
PDGF-BB (pg/mL)	667.33 (605.50)
RANTES (pg/mL)	3689.96 (1421.64)
TNF-alfa (pg/mL)	25.33 (6.50)
TRP (µg/mL)	12.18 (2.36)
KYN (ng/mL)	0.22 (0.20)
3HK (ng/mL)	24.38 (34.40)
KYNA (ng/mL)	8.40 (4.45)
QUIN (ng/mL)	107.92 (41.56)
KYN/Trp*1000 ratio	18.98 (17.58)
KYNA/QUIN ratio	16.59 (11.11)
KYNA/KYN*1000 ratio	88.34 (95.21)
3-HK/KYN ratio	129.20 (115.51)

Table 2
Demographic and clinical characteristics of the longitudinal arm.

Demographic characteristics	T0 Mean (Standard Deviation)	T1 Mean (Standard Deviation)
Age	36.85 (11.59)	
Education	11.41 (2.82)	
Sex (M/F. % M)	66.66 % M	
Onset	21.16 (4.20)	
Duration of illness (years)	15.82 (11.50)	
Chlorpromazine equivalents	469.76 (277.11)	
PANSS		
PANSS Positive	19.38 (6.82)	18.25 (6.63)
PANSS Negative	22.72 (6.98)	22.16 (8.57)
PANSS General	42.36 (11.13)	38.23 (12.08)
PANSS Total	84.46 (21.59)	78.67 (24.27)
MATRICS		
Processing Speed	30.38 (15.13)	31.57 (15.10)
Attention	36.83 (10.68)	33.54 (14.85)
Working Memory	35.64 (14.33)	35.34 (16.56)
Verbal Learning	37.38 (9.93)	39.18 (10.62)
Visual Learning	31.05 (10.03)	32.98 (14.29)
Reasoning	36.00 (9.57)	38.32 (9.67)

Table 3
levels of biomarkers of the longitudinal arm at baseline.

Biomarkers	T0 Mean (Standard Deviation)
IL-1beta (pg/mL)	1.55 (1.63)
IL-1ra (pg/mL)	239.85 (216.46)
IL-6 (pg/mL)	5.10 (10.10)
IL-9 (pg/mL)	550.32 (72.35)
IL-10 (pg/mL)	3.70 (1.07)
IL-13 (pg/mL)	2.17 (1.82)
IL-17 A (pg/mL)	6.52 (3.71)
IFN-gamma (pg/mL)	2.06 (1.24)
MIP-1alfa (pg/mL)	1.23 (0.35)
PDGF-BB (pg/mL)	666.92 (481.12)
RANTES (pg/mL)	3850.38 (1613.47)
TNF-alfa (pg/mL)	25.14 (5.57)
TRP (µg/mL)	12.61 (3.01)
KYN (ng/mL)	103.52 (34.78)
3HK (ng/mL)	8.23 (3.39)
KYNA (ng/mL)	10.92 (3.99)
QUIN (ng/mL)	91.00 (49.50)
KYN/Trp*1000 ratio	8.52 (3.15)
KYNA/QUIN ratio	0.36 (0.80)
KYNA/KYN*1000 ratio	130.89 (101.18)
3-HK/KYN ratio	98.62 (85.46)
ANP	12.88 (10.84)

Table 4
Partial correlations between inflammatory biomarkers and cognition.

	Process. Speed n = 37		Attention n = 22		Working Mem. n = 37		Verb. Learning n = 37		Vis. Learning n = 23		Reasoning n = 37	
	r	p	r	P	r	p	r	p	r	p	r	p
	IL-1β	0.091	0.58	-0.04	0.852	-0.027	0.869	0.061	0.714	-0.165	0.431	-0.147
IL-1ra	-0.128	0.438	0.056	0.794	-0.087	0.6	-0.183	0.266	0.039	0.855	-0.146	0.375
IL-6	0.128	0.438	-0.033	0.877	0.056	0.733	-0.08	0.629	0.384	0.058	0.098	0.554
IL-9	-0.113	0.494	-0.279	0.187	-0.101	0.541	-0.12	0.467	0.133	0.528	-0.093	0.574
IL-10	0.025	0.88	-0.061	0.775	-0.139	0.4	-0.003	0.987	-0.151	0.472	0.118	0.474
IL-13	0.101	0.54	0.206	0.335	0.225	0.168	0.168	0.307	-0.125	0.551	0.123	0.456
IL-17 A	-0.106	0.521	0.041	0.848	-0.304	0.06	-0.345	0.031	-0.139	0.508	-0.206	0.209
IFN-γ	-0.108	0.512	-0.033	0.877	-0.123	0.454	-0.209	0.202	0.209	0.317	-0.113	0.492
MIP-1α	-0.149	0.365	-0.091	0.673	-0.094	0.569	-0.098	0.554	0.145	0.488	-0.185	0.261
PDGF-BB	-0.191	0.244	-0.318	0.13	-0.212	0.194	-0.096	0.562	0.276	0.183	-0.141	0.392
RANTES	0.051	0.757	-0.179	0.404	-0.055	0.74	0.022	0.895	-0.048	0.822	-0.106	0.519
TNF-α	-0.226	0.167	-0.194	0.364	-0.271	0.095	-0.263	0.105	0.09	0.67	-0.188	0.253
ANP	0.25	0.05	-0.169	0.355	0.059	0.652	0.087	0.511	-0.013	0.929	0.138	0.292

3.2. Correlation between cognitive domains and plasma biomarkers

Baseline partial correlations in the whole study sample between plasma levels of inflammatory and ANP with cognition (subscores of the MCCB) as well as KP biomarkers and cognition (subscores of the MCCB) using age and sex as control variables are reported in Tables 4 and 5, respectively.

We found significant negative associations between IL-17 A levels and Verbal learning ($r = -0.345$; $p = 0.031$) and Trp levels and Visual learning ($r = -0.265$; $p = 0.048$). A positive association emerged between ANP levels and Processing speed ($r = 0.25$; $p = 0.05$).

3.3. Cluster analysis of study population based on the neurocognitive profile

The analysis produced two clusters of patients: Cluster 1 (low neurocognitive profile) and Cluster 2 (high neurocognitive profile) as shown in Fig. 2. The Bayesian information criterion (BIC) was 305.87 for the two-cluster solution, also confirmed by the cohesion index and the separation of the silhouettes. Cluster 1 was formed by 36 patients and Cluster 2 by 28 patients, as only 64 of 72 patients completed all the cognitive subtests of the MATRICS Consensus Cognitive Battery needed for the clustering. The longitudinal arm was composed by 26 patients from Cluster 1 and 14 patients from Cluster 2 (the remaining two patients of the longitudinal arm not classified as Cluster 1 or Cluster 2 pertain to the patients that at baseline did not complete all the cognitive subtests). The demographic clinical and cognitive data of the two clusters are reported in Table 1S, while the levels of biomarkers of the two clusters are reported in Table 2S (Supplementary Materials and Methods).

3.4. Correlation between cognitive domains and plasma biomarkers depending on cognitive profiles

3.4.1. Patients with lower neurocognitive profile

Partial correlations between plasma levels of inflammatory biomarkers and cognition at baseline in Cluster 1 showed a positive association between ANP levels and Processing speed ($r = 0.566$; $p = 0.003$). Regarding the KP, Processing speed resulted negatively associated to the activation of the pathway (KYN/Trp ratio) ($r = -0.443$; $p = 0.011$) as well as to the levels of KYN ($r = -0.4$; $p = 0.023$) and 3-HK ($r = -0.428$; $p = 0.015$). Visual learning resulted negatively associated to 3-HK ($r = -0.409$; $p = 0.002$) and KYN levels ($r = -0.408$; $p = 0.002$). Positive associations emerged between KYNA levels and Processing speed ($r = 0.402$; $p = 0.023$) and 3-HK/KYN ratio and reaction times in the Attention task, thus highlighting a negative association with Attention ($r = 0.528$; $p = 0.012$). Details of partial correlations are reported in Table 3S (Supplementary Materials and Methods).

Table 5
Partial correlations between KP biomarkers and cognition.

	Process. Speed n = 72		Attention n = 37		Working Mem. n = 72		Verb. Learning n = 72		Vis. Learning n = 54		Reasoning n = 72	
	r	p	r	p	r	p	r	p	r	p	r	p
TRP	0.091	0.44	-0.145	0.379	-0.039	0.742	0.177	0.132	-0.265	0.048	0.041	0.728
KYN	-0.16	0.172	-0.02	0.903	-0.05	0.67	-0.033	0.777	-0.181	0.183	0.05	0.672
3HK	-0.149	0.205	-0.034	0.838	-0.069	0.557	-0.166	0.156	-0.175	0.196	-0.08	0.499
KYNA	0.141	0.23	-0.144	0.383	-0.002	0.983	0.157	0.183	0.059	0.665	0.02	0.863
QU	-0.001	0.993	0.048	0.771	0.11	0.349	0.107	0.363	0.079	0.564	0.017	0.888
KYN/Trp	-0.152	0.195	0.083	0.616	-0.016	0.891	-0.067	0.569	-0.082	0.55	0.032	0.784
QU/KYA	-0.123	0.298	0.089	0.589	0.11	0.349	0.019	0.872	0.051	0.712	0.027	0.818
KYA/KYA	0.193	0.099	-0.042	0.799	0.167	0.156	0.161	0.171	0.248	0.065	0.059	0.616
3HK/KYN	0.008	0.944	0.229	0.161	0.144	0.221	-0.147	0.212	0.173	0.202	-0.005	0.967




Fig. 2. Separation of the silhouettes based on cognition for Cluster 1 and Cluster 2.

3.4.2. Patients with higher neurocognitive profile

Partial correlations between inflammatory biomarkers and cognition at baseline in Cluster 2 showed that Working memory is negatively associated with IL-17 A ($r = -0.567$; $p = 0.043$), IL-9 ($r = -0.562$; $p = 0.045$), TNF- α ($r = -0.640$; $p = 0.019$), MIP1 α ($r = -0.587$; $p = 0.035$), PDGF-BB ($r = -0.693$; $p = 0.009$) and RANTES ($r = -0.623$; $p = 0.023$). However, MIP1 α showed also a negative association with reaction times ($r = -0.581$; $p = 0.048$). With regards to the KP, KYNA levels showed a negative association with Reasoning ($r = -0.409$; $p = 0.047$) and QUIN a positive correlation with Attention ($r = -0.565$; $p = 0.018$). Details of partial correlations are reported in Table S4 (Supplementary Materials and Methods).

3.5. Relationships between basal biomarkers and cognition after the interventions

To investigate the predictive role of the plasma biomarkers at baseline on the cognitive outcome after the interventions (CRT or AE or CRT + AE) we performed multiple stepwise regressions on the all sample using the $\Delta(T1-T0)$ of the MCCB scores as dependent variables. Using the ratios QUIN/KYNA, 3-HK/KYN, KYN/Trp and KYNA/KYN as predictors, 3-HK/KYN explained cognitive improvements in Processing speed ($\beta = 0.349$; $R^2 = 0.194$; $p = 0.028$) and Reasoning ($\beta = 0.463$; $R^2 = 0.247$; $p = 0.002$), while QUIN/KYNA negatively predicted the improvement in Reasoning ($\beta = -0.358$; $R^2 = 0.247$; $p = 0.014$). Finally, among the pro-inflammatory cytokines, using TNF- α , IL-17 A and ANP as predictors, it was shown that levels of TNF- α hampered improvements in Visual learning ($\beta = -0.487$; $R^2 = 0.182$; $p = 0.05$) (See Tables 6 and 7) (See Figs. 3 and 4).

Table 6

Regression model with QUIN/KYNA, 3-HK/KYN, KYN/Trp and KYNA/KYN as predictors and $\Delta(T1-T0)$ Processing Speed as dependent variable; $R^2 = 0.247$.

	Beta	Std. Err.	B	Std. Err.	t(38)	p-level
Intercept			0.309	0.214	1.446	0.156
T0_3-HK/KYN ratio	0.463	0.140	0.003	0.001	3.330	0.002
T0_QA/KYNA ratio	-0.358	0.139	-0.023	0.009	-2.572	0.014

Table 7

Regression model with QUIN/KYNA, 3-HK/KYN, KYN/Trp and KYNA/KYN as predictors and $\Delta(T1-T0)$ Reasoning as dependent variable; $R^2 = 0.194$.

	Beta	Std. Err.	B	Std. Err.	t(37)	p-level
Intercept			-0.357	0.165	-2.161	0.037
T0_QA/KYNA ratio	0.248	0.161	0.01	0.006	1.534	0.133
T0_3-HK/KYN ratio	0.349	0.153	0.001	0.000	2.275	0.028
T0_Kyn/Trp*1000 ratio	0.191	0.164	0.005	0.004	1.168	0.250

4. Discussion

To our knowledge, this is the first study to address the effects of both inflammatory markers and KP metabolites on cognitive performance in schizophrenia, in particular to disentangle their differential impact depending on the cognitive phenotype and to test their predictive role on the cognitive outcome after rehabilitation.

We observed that cognitive functions in patients with a higher




Fig. 3. Effect of 3HK/KYN ratio and 3HK/KYN and QUIN/KYNA ratio on Processing Speed.




Fig. 4. Effect of TNF- α on Visual Learning.

cognitive profile are primarily and adversely influenced by levels of cytokines and chemokines, rather than by KP metabolites. Conversely, in patients with a lower cognitive profile, KP metabolites tend to exert a more significant impact on cognitive functions compared to cytokines and chemokines.

Our findings align with previous literature reviewed in Sapienza et al. (Sapienza et al., 2023b) demonstrating correlations between both inflammatory and KP measures and cognitive abilities in key domains. However, our results offer new insights into a potential differential impact of the two pathways, suggesting distinct patterns of association based on cognitive profiles.

Moreover, when assessing the influence of baseline markers on cognitive improvement after rehabilitative interventions, we identified significant effects of QUIN/KYNA, 3-HK/KYN, and TNF- α . The QUIN/KYNA ratio, along with TNF- α , negatively predicted cognitive improvements, indicating a detrimental role of QUIN and a positive role of KYNA, consistent with baseline findings. Conversely, 3-HK/KYN predicted favorable cognitive outcomes. Despite the property of the immune system to activate the KP, our mediation models did not show the ability of TNF- α to influence the impact of KP metabolites on cognitive

functions. This was probably due to the low sample size.

Regarding the cross-sectional arm, the greater impact of inflammatory biomarkers on working memory in patients with a higher cognitive functioning might be due to a greater susceptibility to the oxidative stress and cytotoxicity exerted by neuroinflammation (Maas et al., 2017; Fourrier et al., 2019; Kindler et al., 2020; Patlola et al., 2023). It is to note that individuals with greater cortical volumes and WM integrity show less cognitive impairment and, for this reason, they might be more exposed to the detrimental effect of inflammation as the biological substrates of cognition are more preserved (Ehrlich et al., 2012; Castro-de-Araujo et al., 2018; Yamada et al., 2022; Kilian et al., 2022; Fan et al., 2022). As a matter of facts, neurons' dendrites and axons contributed to volume composition of the cortex with 30 % and 29 % respectively (Howes et al., 2023) and brain sub-inflammation induces neuron loss, enhanced synaptic pruning and white matter (WM) disruption (Zhang et al., 2016; Uranova et al., 2020; Michalczyk et al., 2022). Among these pathogenic factors, the oxidative stress is mainly involved in myelin disruption and cellular death, thus the loss of both somas and dendritic ramifications, while synaptic pruning is involved in the downsizing of dendritic arborizations and loss of synapses (Howes and McCutcheon, 2017; North et al., 2021). Overall, these pathogenic processes triggered by inflammation damage individuals with greater cognitive reserve the most, through a progressive reduction of cortical volumes (Vita et al., 2012; North et al., 2021; Kindler et al., 2020). The intriguing negative correlations observed between peripheral biomarkers MIP1 α , RANTES, and PDGF-BB and working memory underscore the impact of systemic inflammation on cognitive functions. This finding supports the significance of brain-periphery immune crosstalk in determining cognitive impairment, as evidenced by previous studies (Cervenka et al., 2017; North et al., 2021), and the importance to target peripheral sub-inflammation, typical of the dysmetabolic condition associated to schizophrenia, with AE, to resize cognitive deficits (Della Guardia and Codella, 2021). In essence, it is conceivable that disrupted molecular-level circuits and a reduced number of neuronal somas may impede the retention of "data" in working memory. Considering patients with a lower cognitive profile, we found that the KP plays a prominent role on cognitive performance compared to neuroinflammation. One hypothesis is that the integrity of cortical layers is already compromised in these patients, then the pathogenic processes induced by inflammatory biomarkers cannot induce further significant cognitive impairments. Notably, KP metabolites due to a wide range of neuromodulatory, neurotoxic and neuroprotective properties might impact cognition when the action of inflammatory factors seemed less impactful (Sas et al.,

2018; Sapienza et al., 2023b). Overall, in this sub-sample of patients the activation of the KP (as shown by higher KYN levels and KYN/Trp ratio) is detrimental to cognition as also shown by previous findings (Sapienza et al., 2023b), specifically to processing speed and visual learning. However, implications for other cognitive domains depend on the activity of two of the most important enzymes of the pathway, thus on the metabolic activity along the two branches of the KP. If KYN is metabolized by KMO leading to the production of 3-HK, considering the 3-HK/KYN ratio as a proxy of KMO enzymatic activity, negative effects are observed, particularly in the domains of visual learning and attention. Differently, if KYN is converted into KYNA by KAT, positive effects were shown on Processing speed (Amori et al., 2009). Interestingly, KYNA showed strong antioxidant and neuroprotective properties and the ability to regulate neuronal excitability and plasticity by modulating the expression of cholinergic receptors via the inhibition of alpha 7 nAChR activity, which induces an increased density of non-7 nicotinic receptors (Hilmas et al., 2001; Lugo-Huitrón et al., 2011). Moreover, it elicits a negative allosteric modulation on NMDA receptors which can prevent excitotoxicity and a positive modulatory action at the binding site of the AMPA receptor which can enhance excitatory synaptic transmission (Prescott et al., 2006). Regarding 3-HK, known for its neurotoxic properties causing oxidative damage and cell death (Castellano-Gonzalez et al., 2019), it serves as a precursor to QUIN, an excitotoxin acting on NMDA receptors. There is evidence for a synergistic negative interaction between QUIN and 3-HK (Guidetti and Schwarcz, 1999). Activation of the KMO branch may thus lead to a dual negative impact on cognitive functions.

Regarding the results emerged in the longitudinal arm, the QUIN/KYNA ratio negatively predicted improvements in Reasoning. As above-mentioned, several findings reported a neurotoxic effect of QUIN (Guillemin, 2012; Sas et al., 2018; Cathomas et al., 2021). Specifically, QUIN is an agonist at the NMDA receptor and the continuous stimulation of NMDA receptors can cause excitotoxic cell death (Prado De Carvalho et al., 1996; Brown et al., 1998; Shah et al., 2020). In addition to NMDA receptor agonism, it also induces lipid peroxidation (Rodríguez-Martínez et al., 2000), produces Reactive Oxygen Species (ROS), increases the inducible Nitric Oxide Synthase (iNOS) expression, decreases Superoxide dismutase (SOD) activity and causes mitochondrial dysfunction (Sahm et al., 2013). Moreover, it is also toxic to oligodendrocytes (Cammer, 2001), thus can be involved in demyelination processes. Interestingly, Cathomas et al. reported that QUIN levels were inversely related to the composite cognitive score in schizophrenia (Cathomas et al., 2021) and Cogo et al. described a QUIN/KYNA as a reliable biomarker of cognitive decline in individuals after stroke (Cogo et al., 2021). On the contrary, the 3-HK/KYN ratio, an index of KMO activity, showed the ability to predict the improvements in Processing speed and Reasoning. Such discrepancy with respect to the baseline findings might be explained by the dual action of 3-HK. Indeed, despite 3-HK is mainly described as neurotoxic, many findings showed neuroprotective and antioxidant properties of such molecule, highlighting its dual action (Colín-González et al., 2013; Colín-González et al., 2014). Indeed, 3-HK is capable of inducing oxidative damage and cell death but also to exert antioxidant and scavenging properties targeting ROS as nitric oxide (NO), oxygen (O₂), hydroxide (HO) and peroxy radical (ROO) (Goda et al., 1999; Leipnitz et al., 2007; Backhaus et al., 2008). As certain vitamins and metabolites that show this double behavior, the dual action of 3-HK is likely to depend on its concertation and/or the interactions with other molecules in the environment or on the modifications induced by these molecules on the environment (Colín-González et al., 2013). Therefore, the biological/molecular modifications induced by the rehabilitative strategies could enhance the neuroprotective properties of 3-HK in a synergistic manner. For instance, AE showed the ability to induce changes in the redox environment decreasing the glutathione (GSH) to oxidized glutathione (GSSG) ratio, an index of oxidative stress, and increasing malondialdehyde (Chapul et al., 2022). Interestingly, these changes could enhance the antioxidant properties of 3-HK.

Overall, the equilibrium between the neurotoxic and neuroprotective attributes of neuroactive metabolites plays a crucial role in influencing processing speed and reasoning. This impact could stem from the balance of such compounds, which is important for the integrity of neural cytoarchitecture and the networks responsible for processing nervous signals, thus processing of the information. Another important finding is that TNF- α levels hamper the effect of rehabilitation strategies on Visual learning. Notably, TNF- α is one of the main pro-inflammatory cytokines involved in the pathogenesis of schizophrenia and several findings reported increased TNF- α levels in patients (Potvin et al., 2008; Miller et al., 2013; Uptegrove et al., 2014; Momtazmanesh et al., 2019). Specifically, a meta-analysis by Uptegrove and colleagues including 570 First-episode Psychosis (FEP) patients found increased levels of several pro-inflammatory cytokines, and particularly TNF- α (Uptegrove et al., 2014). Moreover, associations between TNF- α and cognitive decline were also reported in schizophrenia and other populations (McAfoose et al., 2009; Morrens et al., 2022; Morrens et al., 2022), but the more interesting finding supporting the detrimental role of TNF-signaling during AE was reported by Morgan and colleagues, who demonstrated its negative modulatory effect on the cognitive improvements elicited by AE in mice (Morgan et al., 2018). Therefore, the pro-inflammatory state induced by basal TNF- α levels probably sustains the activation of microglia, neurodegeneration, WM disruption and increased synaptic pruning, hampering the cognitive improvements induced by rehabilitation strategies (North et al., 2021).

4.1. Limits and future directions

A major limitation of this study is the small sample size, especially in the longitudinal arm, hindering the inclusion of confounding factors and assessment of predictors for each intervention. Hypotheses are at times based on indirect evidence, warranting further validation in larger randomized controlled trials. Moreover, although MCCB is a validated and widely used scale for the cognitive assessment in schizophrenias, particularly in clinical trials (Nuechterlein et al., 2008) (Nuechterlein et al., 2023), it is quite long and complex. Therefore, we cannot rule out that the integrity and objectivity of data acquisition are not affected by such aspect. Another point to acknowledge is that the choice of the type of AE intervention may affect adherence, thus we opted for cycle-ergometer. Future studies should incorporate neuroimaging and a broader panel of biological markers to better understand the complex interactions among multiple biological systems and their potential as cognitive enhancement targets. Thorough clusterization based on specific cognitive functions would likely enhance the relationship between cognitive performance and its molecular underpinnings.

5. Conclusion

While preliminary, our findings are noteworthy as they indicate dissociated effects of inflammatory markers and kynurenes on cognitive performance in schizophrenia, depending on the cognitive phenotype of the patients. In particular, a predominant effect of inflammation is observed among patients with relatively preserved cognitive abilities, while the KP plays a major role in patients with more severe deficits. Furthermore, the predictive effects of QUIN/KYNA, 3-HK/KYN, and TNF- α on the extent of cognitive improvement not only support their direct relation to cognition but also suggest these pathways may play a role in the dynamic modulation of cognition. This indicates that they could serve as substrates influenced by ongoing training interventions and as potential targets for future drug discovery programs.

Fundings

This study was funded by the Italian Ministry of Health under Grant Number GR-2016-02361538 ("Walking our way to a healthier brain: a randomized controlled trial to evaluate the effects of aerobic exercise,

cognitive remediation and combined intervention in schizophrenia”).

CRedit authorship contribution statement

Jacopo Sapienza: Writing – original draft, Conceptualization. **Giulia Agostoni:** Software, Formal analysis, Data curation. **Sofia Nasini:** Formal analysis. **Stefano Dall’Acqua:** Formal analysis. **Stefania Sut:** Formal analysis. **Marco Spangaro:** Project administration, Methodology. **Francesca Martini:** Methodology. **Margherita Bechi:** Project administration, Methodology. **Mariachiara Buonocore:** Methodology. **Giorgia Bigai:** Data curation. **Daniela Nocera:** Data curation. **Chiara Ave:** Data curation. **Carmelo Guglielmino:** Project administration. **Federica Cocchi:** Data curation. **Roberto Cavallaro:** Validation, Project administration. **Giacomo Deste:** Project administration. **Marta Bosia:** Writing – review & editing, Validation, Project administration, Methodology, Funding acquisition, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scog.2024.100328>.

References

- Amori, L., Guidetti, P., Pellicciari, R., Kajii, Y., Schwarcz, R., 2009. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. *J. Neurochem.* 109, 316–325. <https://doi.org/10.1111/J.1471-4159.2009.05893.X>.
- Backhaus, C., Rahman, H., Scheffler, S., Laatsch, H., Hardeland, R., 2008. NO scavenging by 3-hydroxyanthranilic acid and 3-hydroxykynurenine: N-nitrosation leads via oxadiazoles to o-quinone diazides. *Nitric Oxide Biol. Chem.* 19, 237–244. <https://doi.org/10.1016/J.NIOX.2008.07.002>.
- Bechthold, A., Knost, B., Kuntermann, C., Schiller, S., Klosterkötter, J., Hambrecht, M., Pukrop, R., 2004. A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. *Acta Psychiatr. Scand.* 110, 21–28. <https://doi.org/10.1111/J.1600-0447.2004.00300.X>.
- Bechi, M., Spangaro, M., Agostoni, G., Bosinelli, F., Buonocore, M., Bianchi, L., Cocchi, F., Guglielmino, C., Bosia, M., Cavallaro, R., 2019. Intellectual and cognitive profiles in patients affected by schizophrenia. *J. Neuropsychol.* 13, 589–602. <https://doi.org/10.1111/JNP.12161>.
- van Berckel, B.N., Bossong, M.G., Boellaard, R., Kloet, R., Schuitmaker, A., Caspers, E., Luurtsema, G., Windhorst, A.D., Cahn, W., Lammertsma, A.A., Kahn, R.S., 2008. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK1195 positron emission tomography study. *Biol. Psychiatry* 64, 820–822. <https://doi.org/10.1016/j.biopsych.2008.04.025>.
- Bosia, M., Bechi, M., Marino, E., Anselmetti, S., Poletti, S., Cocchi, F., Smeraldi, E., Cavallaro, R., 2007. Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. *Neurosci. Lett.* 417, 271–274. <https://doi.org/10.1016/j.neulet.2007.02.076>.
- Bosia, M., Spangaro, M., Sapienza, J., Martini, F., Civardi, S., Buonocore, M., Bechi, M., Lorenzi, C., Cocchi, F., Bianchi, L., Guglielmino, C., Cavallaro, R., 2021. Cognition in schizophrenia: modeling the interplay between interleukin-1 β C-511T polymorphism, metabolic syndrome, and sex. *Neuropsychobiology* 80, 321–332. <https://doi.org/10.1159/000512082>.
- Bosia, M., Spangaro, M., Cocchi, F., Sapienza, J., Tonet, L., Martini, F., Fregna, L., Passani, C., Cavallaro, R., 2022. Psychotic disorders. In: Cavallaro, R., Colombo, C. (Eds.), *Fundamentals of Psychiatry for Health Care Professionals*. Springer, p. 456. <https://doi.org/10.1007/978-3-031-07715-9>.
- Boyer, L., Testart, J., Michel, P., Richieri, R., Faget-Agius, C., Vanoye, V., Auquier, P., Lancon, C., Guedj, E., 2014. Neurophysiological correlates of metabolic syndrome and cognitive impairment in schizophrenia: a structural equation modeling approach. *Psychoneuroendocrinology* 50, 95–105. <https://doi.org/10.1016/j.psneuen.2014.07.019>.
- Braver, T.S., Barch, D.M., Cohen, J.D., 1999. Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function. *Biol. Psychiatry* 46, 312–328. [https://doi.org/10.1016/S0006-3223\(99\)00116-X](https://doi.org/10.1016/S0006-3223(99)00116-X).
- Brown, J.C., Tse, H.W., Skifter, D.A., Christie, J.M., Andaloro, V.J., Kemp, M.C., Watkins, J.C., Jane, D.E., Monaghan, D.T., 1998. [3H]homoquinoline binds to a subpopulation of NMDA receptors and to a novel binding site. *J. Neurochem.* 71, 1464–1470. <https://doi.org/10.1046/J.1471-4159.1998.71041464.X>.
- Buonocore, M., Spangaro, M., Bechi, M., Trezzani, S., Terragni, R., Martini, F., Agostoni, G., Cocchi, F., Cuoco, F., Guglielmino, C., Bosia, M., Cavallaro, R., 2022. Cognitive remediation in schizophrenia: what happens after 10 years? *Schizophr. Res. Cogn.* 29, 100251. <https://doi.org/10.1016/J.SCOG.2022.100251>.
- Cammer, W., 2001. Oligodendrocyte killing by quinolinic acid in vitro. *Brain Res.* 896, 157–160. [https://doi.org/10.1016/S0006-8993\(01\)02017-0](https://doi.org/10.1016/S0006-8993(01)02017-0).
- Castellano-Gonzalez, G., Jacobs, K.R., Don, E., Cole, N.J., Adams, S., Lim, C.K., Lovejoy, D.B., Guillemin, G.J., 2019. Kynurenine 3-monooxygenase activity in human primary neurons and effect on cellular bioenergetics identifies new neurotoxic mechanisms. *Neurotox. Res.* 35, 530–541. <https://doi.org/10.1007/S12640-019-9997-4>.
- Castro-de-Araujo, L.F.S., Allin, M., Picchioni, M.M., McDonald, C., Pantelis, C., Kanaan, R.A.A., 2018. Schizophrenia moderates the relationship between white matter integrity and cognition. *Schizophr. Res.* 199, 250–256. <https://doi.org/10.1016/J.SCHRES.2018.03.033>.
- Cathomas, F., Guetter, K., Seifritz, E., Klaus, F., Kaiser, S., 2021. Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. *Sci. Rep.* 11, 9992. <https://doi.org/10.1038/S41598-021-89335-9>.
- Cavallaro, R., Anselmetti, S., Poletti, S., Bechi, M., Ermoli, E., Cocchi, F., Stratta, P., Vita, A., Rossi, A., Smeraldi, E., 2009. Computer-aided neurocognitive remediation as an enhancing strategy for schizophrenia rehabilitation. *Psychiatry Res.* 169, 191–196. <https://doi.org/10.1016/J.PSYCHRES.2008.06.027>.
- Cervenka, I., Agudelo, L.Z., Ruas, J.L., 2017. Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health. *Science* 357, eaaf9794. <https://doi.org/10.1126/SCIENCE.AAF9794>.
- Chapul, L.S., de la Cruz, G.P., Chávez, L.A.R., León, J.F.V., Beltrán, J.T., Camarena, E.E., Mora, P.C., Ortega, D.R., Vázquez, J.U.B., Nava, G.M., Angulo, A.L., Canseco, C.M., Chirino, T.Y.W., Martínez, J.R., de la Cruz, V.P., 2022. Characterization of redox environment and tryptophan catabolism through kynurenine pathway in military divers’ and swimmers’ serum samples. *Antioxidants (Basel, Switzerland)* 11, 1223. <https://doi.org/10.3390/ANTIOX11071223>.
- Cogo, A., Mangin, G., Maier, B., Callebert, J., Mazighi, M., Chabriat, H., Launay, J.M., Huberfeld, G., Kubis, N., 2021. Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline. *Mol. Neurodegener.* 16, 1–20. <https://doi.org/10.1186/s13024-020-00421-4>.
- Colín-González, A.L., Maldonado, P.D., Santamaría, A., 2013. 3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system. *Neurotoxicology* 34, 189–204. <https://doi.org/10.1016/j.neuro.2012.11.007>.
- Colín-González, A.L., Maya-López, M., Pedraza-Chaverrí, J., Ali, S.F., Chavarría, A., Santamaría, A., 2014. The Janus faces of 3-hydroxykynurenine: dual redox modulatory activity and lack of neurotoxicity in the rat striatum. *Brain Res.* 1589, 1–14. <https://doi.org/10.1016/J.BRAINRES.2014.09.034>.
- Comai, S., Bertazzo, A., Brughera, M., Crotti, S., 2020. Tryptophan in health and disease. *Adv. Clin. Chem.* 95, 165–218. <https://doi.org/10.1016/BS.ACC.2019.08.005>.
- Comai, S., Melloni, E., Lorenzi, C., Bollettini, I., Vai, B., Zanardi, R., Colombo, C., Valtorra, F., Benedetti, F., Poletti, S., 2022. Selective association of cytokine levels and kynurenine/tryptophan ratio with alterations in white matter microstructure in bipolar but not in unipolar depression. *Eur. Neuropsychopharmacol.* 55, 96–109. <https://doi.org/10.1016/J.EURONEURO.2021.11.003>.
- Cuoco, F., Agostoni, G., Lesmo, S., Sapienza, J., Buonocore, M., Bechi, M., Martini, F., Ferri, I., Spangaro, M., Bigai, G., Seghi, F., Guglielmino, C., Cocchi, F., Cavallaro, R., Bosia, M., 2022. Get up! Functional mobility and metabolic syndrome in chronic schizophrenia: effects on cognition and quality of life. *Schizophr. Res. Cogn.* 28, 100245. <https://doi.org/10.1016/J.SCOG.2022.100245>.
- Della Guardia, L., Codella, R., 2021. Exercise tolls the bell for key mediators of low-grade inflammation in dysmetabolic conditions. *Cytokine Growth Factor Rev.* 62, 83–93. <https://doi.org/10.1016/J.CYTOGFR.2021.09.003>.
- Domercq, M., Etxebarria, E., Pérez-Samartín, A., Matute, C., 2005. Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. *Glia* 52, 36–46. <https://doi.org/10.1002/GLIA.20221>.
- Ehrlich, S., Brauns, S., Yendiki, A., Ho, B.C., Calhoun, V., Charles Schulz, S., Gollub, R.L., Sponheim, S.R., 2012. Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls. *Schizophr. Bull.* 38, 1050–1062. <https://doi.org/10.1093/SCHBUL/SBR018>.
- Fan, Y., Gao, Y., Ma, Q., Zhao, B., He, X., Zhu, F., Wang, W., Ma, X., Li, Y., 2022. Grey matter volume and its association with cognitive impairment and peripheral cytokines in excited individuals with schizophrenia. *Brain Imaging Behav.* 16, 2618–2626. <https://doi.org/10.1007/S11682-022-00717-7>.
- Firth, J., Stubbs, B., Rosenbaum, S., Vancampfort, D., Malchow, B., Schuch, F., Elliott, R., Nuechterlein, K.H., Yung, A.R., 2017. Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. *Schizophr. Bull.* 43, 546–556. <https://doi.org/10.1093/SCHBUL/SBW115>.
- Fourrier, C., Singhal, G., Baune, B.T., 2019. Neuroinflammation and cognition across psychiatric conditions. *CNS Spectr.* 24, 4–15. <https://doi.org/10.1017/S1092852918001499>.
- Gibbons, A., Dean, B., 2016. The cholinergic system: an emerging drug target for schizophrenia. *Curr. Pharm. Des.* 22, 2124–2133. <https://doi.org/10.2174/1381612822666160127114010>.
- Goda, K., Hamane, Y., Kishimoto, R., Ogishi, Y., 1999. Radical scavenging properties of tryptophan metabolites. Estimation of their radical reactivity. *Adv. Exp. Med. Biol.* 467, 397–402. https://doi.org/10.1007/978-1-4615-4709-9_50.
- Grover, S., R, P., Sahoo, S., Gopal, S., Nehra, R., Ganesh, A., Raghavan, V., Sankaranarayan, A., 2019. Relationship of metabolic syndrome and neurocognitive deficits in patients with schizophrenia. *Psychiatry Res.* 278, 56–64. <https://doi.org/10.1016/j.psychres.2019.05.023>.

- Guidetti, P., Schwarcz, R., 1999. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. *Eur. J. Neurosci.* 11, 3857–3863. <https://doi.org/10.1046/j.1460-9568.1999.00806.x>.
- Guillemin, G.J., 2012. Quinolinic acid: neurotoxicity. *FEBS J.* 279, 1355. <https://doi.org/10.1111/j.1742-4658.2012.08493.x>.
- Harvey, P.D., Bosia, M., Cavallaro, R., Howes, O.D., Kahn, R.S., Leucht, S., Müller, D.R., Penadés, R., Vita, A., 2022. Cognitive dysfunction in schizophrenia: an expert group paper on the current state of the art. *Schizophr. Res. Cogn.* 29, 100249. <https://doi.org/10.1016/j.SCOG.2022.100249>.
- Hilmas, C., Pereira, E.F.R., Alkondon, M., Rassoulpour, A., Schwarcz, R., Albuquerque, E. X., 2001. The brain metabolite kynurenic acid inhibits $\alpha 7$ nicotinic receptor activity and increases non- $\alpha 7$ nicotinic receptor expression: Physiopathological implications. *J. Neurosci.* 21, 7463–7473. <https://doi.org/10.1523/jneurosci.21-19-07463.2001>.
- Howes, O.D., McCutcheon, R., 2017. Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. *Transl. Psychiatry* 7, e1024–11. <https://doi.org/10.1038/tp.2016.278>.
- Howes, O.D., Onwordi, E.C., 2023. The synaptic hypothesis of schizophrenia version III: a master mechanism. *Mol. Psychiatry* 1–14. <https://doi.org/10.1038/s41380-023-02043-w>.
- Howes, O.D., Cummings, C., Chapman, G.E., Shatalina, E., 2023. Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes. *Neuropsychopharmacology* 48, 151–167. <https://doi.org/10.1038/s41386-022-01426-x>.
- Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr. Bull.* 13, 261–276.
- Khandaker, G.M., Cousins, L., Deakin, J., Lennox, B.R., Yolken, R., Jones, P.B., 2015. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. *Lancet Psychiatry* 2, 258–270. [https://doi.org/10.1016/S2215-0366\(14\)00122-9](https://doi.org/10.1016/S2215-0366(14)00122-9).
- Kilian, S., Du Plessis, S., Fouche, J.P., Luckhoff, H., Scheffler, F., Phahladra, L., Buckle, C., Smit, R., Olivier, R., Swartz, L., Emsley, R., Asmal, L., 2022. Differences in white matter microstructure in first-episode schizophrenia spectrum disorders vs healthy volunteers and their association with cognition. *Schizophr. Res.* 250, 196–202. <https://doi.org/10.1016/j.SCHRES.2022.11.017>.
- Kindler, J., Lim, C.K., Weickert, C.S., Boerger, D., Galletly, C., Liu, D., Jacobs, K.R., Balzan, R., Bruggemann, J., O'Donnell, M., Lenroot, R., Guillemin, G.J., Weickert, T. W., 2020. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. *Mol. Psychiatry* 25, 2860–2872. <https://doi.org/10.1038/s41380-019-0401-9>.
- Leipnitz, G., Schumacher, C., Dalcin, K.B., Scussiato, K., Solano, A., Funchal, C., Dutra-Filho, C.S., Wyse, A.T.S., Wannmacher, C.M.D., Latini, A., Wajner, M., 2007. In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain. *Neurochem. Int.* 50, 83–94. <https://doi.org/10.1016/j.NEUNET.2006.04.017>.
- Lugo-Huitrón, R., Blanco-Ayala, T., Ugalde-Muñiz, P., Carrillo-Mora, P., Pedraza-Chaverri, J., Silva-Adaya, D., Maldonado, P.D., Torres, I., Pinzón, E., Ortiz-Islas, E., López, T., García, E., Pineda, B., Torres-Ramos, M., Santamaría, A., La Cruz, V.P. De, 2011. On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. *Neurotoxicol. Teratol.* 33, 538–547. <https://doi.org/10.1016/j.NTT.2011.07.002>.
- Maas, D.A., Vallès, A., Martens, G.J.M., 2017. Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. *Transl. Psychiatry* 7, e1171. <https://doi.org/10.1038/tp.2017.138>.
- Martin, K.S., Azzolini, M., Ruas, J.L., 2020. The kynurenine connection: how exercise shifts muscle tryptophan metabolism and affects energy homeostasis, the immune system, and the brain. *Am. J. Phys. Cell Phys.* 318, C818–C830. <https://doi.org/10.1152/ajpcell.00580.2019>.
- Matsuda, Y., Makinodan, M., Morimoto, T., Kishimoto, T., 2019. Neural changes following cognitive remediation therapy for schizophrenia. *Psychiatry Clin. Neurosci.* 73, 676–684. <https://doi.org/10.1111/PCN.12912>.
- Matute, C., Alberdi, E., Domercq, M., Sánchez-Gómez, M.V., Pérez-Samartín, A., Rodríguez-Antigüedad, A., Pérez-Cerdá, F., 2007. Excitotoxic damage to white matter. *J. Anat.* 210, 693–702. <https://doi.org/10.1111/j.1469-7580.2007.00733.x>.
- McAfoose, J., Koerner, H., Baune, B.T., 2009. The effects of TNF deficiency on age-related cognitive performance. *Psychoneuroendocrinology* 34, 615–619. <https://doi.org/10.1016/j.PSYNEUEN.2008.10.006>.
- Messaoud, A., Rym, M., Wahiba, D., Neffati, F., Najjar, M.F., Gobbi, G., Manchia, M., Valterra, F., Lotfi, G., Comai, S., 2022. Investigation of the relationship among cortisol, pro-inflammatory cytokines, and the degradation of tryptophan into kynurenine in patients with major depression and suicidal behavior. *Curr. Top. Med. Chem.* 22, 2119–2125. <https://doi.org/10.2174/1568026621666210909160210>.
- Michalczyk, A., Tyburski, E., Podwalski, P., Waszczuk, K., Rudkowski, K., Kucharska-Mazur, J., Mak, M., Rek-Owodziń, K., Plichta, P., Bielecki, M., Andrusiewicz, W., Czerska-Heryć, E., Samochowick, A., Misiak, B., Sagan, L., Samochowick, J., 2022. Serum inflammatory markers and their associations with white matter integrity of the corpus callosum in schizophrenia patients and healthy controls. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 116, 110510. <https://doi.org/10.1016/j.PNPBP.2022.110510>.
- Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., 2011. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. *Biol. Psychiatry* 70, 663–671. <https://doi.org/10.1016/j.biopsych.2011.04.013>.
- Miller, B.J., Gassama, B., Sebastian, D., Buckley, P., Mellor, A., 2013. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. *Biol. Psychiatry* 73, 993–999. <https://doi.org/10.1016/j.biopsych.2012.09.007>.
- Moghaddam, B., Javitt, D., 2012. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. *Neuropsychopharmacology* 37, 4–15. <https://doi.org/10.1038/npp.2011.181>.
- Moghaddam, B., Adams, B., Verma, A., Daly, D., 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. *J. Neurosci.* 17, 2921–2927. <https://doi.org/10.1523/JNEUROSCI.17-08-02921.1997>.
- Momtazmanesh, S., Zare-Shahabadi, A., Rezaei, N., 2019. Cytokine alterations in schizophrenia: an updated review. *Front. Psychol.* 10, 892. <https://doi.org/10.3389/FPSYT.2019.00892>.
- Morgan, J.A., Singhal, G., Corrigan, F., Jaehne, E.J., Jawahar, M.C., Baune, B.T., 2018. TNF signalling via the TNF receptors mediates the effects of exercise on cognition-like behaviours. *Behav. Brain Res.* 353, 74–82. <https://doi.org/10.1016/j.BBR.2018.06.036>.
- Morrens, M., Overloop, C., Coppens, V., Loots, E., Van Den Noortgate, M., Vandenamee, S., Leboyer, M., De Picker, L., 2022. The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis. *Mol. Psychiatry* 27, 3237–3246. <https://doi.org/10.1038/s41380-022-01582-Y>.
- North, H.F., Bruggemann, J., Cropley, V., Swaminathan, V., Sundram, S., Lenroot, R., Pereira, A.M., Zalesky, A., Bousman, C., Pantelis, C., Weickert, T.W., Shannon Weickert, C., 2021. Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions. *Eur. Arch. Psychiatry Clin. Neurosci.* 271, 595–607. <https://doi.org/10.1007/S00406-021-01237-Z>.
- Nuechterlein, K.H., Green, M.F., Kern, R.S., Baade, L.E., Barch, D.M., Cohen, J.D., Essock, S., Fenton, W.S., Frese, F.J., Gold, J.M., Goldberg, T., Heaton, R.K., Keefe, R. S.E., Kraemer, H., Mesholam-Gately, R., Seidman, L.J., Stover, E., Weinberger, D.R., Young, A.S., Zalcman, S., Marder, S.R., 2008. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. *Am. J. Psychiatry* 165, 203–213. <https://doi.org/10.1176/APPI.AJP.2007.07010042>.
- Nuechterlein, K.H., Green, M.F., Kern, R.S., 2023. The MATRICS consensus cognitive battery: an update. *Curr. Top. Behav. Neurosci.* 63, 1–18. <https://doi.org/10.1007/7854.2022.395>.
- Patola, S.R., Donohoe, G., McKernan, D.P., 2023. The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: a systematic review and meta-analysis. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 121, 110668. <https://doi.org/10.1016/j.PNPBP.2022.110668>.
- Pedraz-Petrozzi, B., Elyamany, O., Rummel, C., Mulert, C., 2020. Effects of Inflammation on the Kynurenine Pathway in Schizophrenia-A Systematic Review, 17, p. 56. <https://doi.org/10.1186/s12974-020-1721-z>.
- Penadés, R., López-Vilchez, I., Catalán, R., Arias, B., González-Rodríguez, A., García-Rizo, C., Masana, G., Ruíz, V., Mezquida, G., Bernardo, M., 2018. BDNF as a marker of response to cognitive remediation in patients with schizophrenia: a randomized and controlled trial. *Schizophr. Res.* 197, 458–464. <https://doi.org/10.1016/j.SCHRES.2017.12.002>.
- Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R., Kouassi, E., 2008. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. *Biol. Psychiatry* 63, 801–808. <https://doi.org/10.1016/j.biopsych.2007.09.024>.
- Prado De Carvalho, L., Bochet, P., Rossier, J., 1996. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. *Neurochem. Int.* 28, 445–452. [https://doi.org/10.1016/0197-0186\(95\)00091-7](https://doi.org/10.1016/0197-0186(95)00091-7).
- Prescott, C., Weeks, A.M., Staley, K.J., Partin, K.M., 2006. Kynurenic acid has a dual action on AMPA receptor responses. *Neurosci. Lett.* 402, 108–112. <https://doi.org/10.1016/j.NEULET.2006.03.051>.
- Roder, V., Brenner, H.D., Müller, D., Lächler, M., Zorn, P., Reisch, T., Bösch, J., Bridler, R., Christen, C., Jaspén, E., Schmidl, F., Schwemmer, V., 2002. Development of specific social skills training programmes for schizophrenia patients: results of a multicentre study. *Acta Psychiatr. Scand.* 105, 363–371. <https://doi.org/10.1034/J.1600-0447.2002.10214.X>.
- Rodríguez-Martínez, E., Camacho, A., Maldonado, P.D., Pedraza-Chaverri, J., Santamaría, D., Galván-Arzate, S., Santamaría, A., 2000. Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. *Brain Res.* 858, 436–439. [https://doi.org/10.1016/S0006-8993\(99\)02474-9](https://doi.org/10.1016/S0006-8993(99)02474-9).
- Sahm, F., Oezen, I., Opitz, C.A., Radlwimmer, B., Von Deimling, A., Ahrendt, T., Adams, S., Bode, H.B., Guillemin, G.J., Wick, W., Platten, M., 2013. The endogenous tryptophan metabolite and NAD⁺ precursor quinolinic acid confers resistance of gliomas to oxidative stress. *Cancer Res.* 73, 3225–3234. <https://doi.org/10.1158/0008-5472.CAN-12-3831>.
- Sapienza, J., Bosia, M., Spangaro, M., Martini, F., Agostoni, G., Cuoco, F., Cocchi, F., Cavallaro, R., 2023a. Schizophrenia and psychedelic state: Dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes. *Mol. Psychiatry* 28, 59–67. <https://doi.org/10.1038/s41380-022-01721-5>.
- Sapienza, J., Spangaro, M., Guillemin, G.J., Comai, S., Bosia, M., 2023b. Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies. *Eur. Arch. Psychiatry Clin. Neurosci.* 273, 1317–1328. <https://doi.org/10.1007/S00406-022-01519-0>.
- Sapienza, J., Agostoni, G., Dall'Acqua, S., Sut, S., Nasini, S., Martini, F., Marchesi, A., Bechi, M., Buonocore, M., Cocchi, F., Cavallaro, R., Spangaro, M., Comai, S., Bosia, M., 2024a. The kynurenine pathway in treatment-resistant schizophrenia at the crossroads between pathophysiology and pharmacotherapy. *Schizophr. Res.* 264, 71–80. <https://doi.org/10.1016/j.schres.2023.12.005>.

- Sapienza, J., Pacchioni, F., Spangaro, M., Bosia, M., 2024b. Dysconnection in schizophrenia: filling the dots from old to new evidence. *Clin. Neurophysiol.* 162, 226–228. <https://doi.org/10.1016/j.clinph.2024.03.013>.
- Sas, K., Szabó, E., Vécsei, L., 2018. Mitochondria, oxidative stress and the kynurenine system, with a focus on ageing and neuroprotection. *Molecules* 23, 1–28. <https://doi.org/10.3390/molecules23010191>.
- Shah, P., Plitman, E., Iwata, Y., Kim, J., Nakajima, S., Chan, N., Brown, E.E., Caravaggio, F., Torres, E., Hahn, M., Chakravarty, M.M., Remington, G., Gerretsen, P., Graff-Guerrero, A., 2020. Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: implications for glutamate-mediated excitotoxicity. *J. Psychiatr. Res.* 124, 151–158. <https://doi.org/10.1016/j.jpsychires.2020.02.032>.
- Shimada, T., Ito, S., Makabe, A., Yamanushi, A., Takenaka, A., Kawano, K., Kobayashi, M., 2022. Aerobic exercise and cognitive functioning in schizophrenia: an updated systematic review and meta-analysis. *Psychiatry Res.* 314, 114656 <https://doi.org/10.1016/j.jpsychires.2022.114656>.
- Spangaro, M., Bosia, M., Zanoletti, A., Bechi, M., Cocchi, F., Pirovano, A., Lorenzi, C., Bramanti, P., Benedetti, F., Smeraldi, E., Cavallaro, R., 2012. Cognitive dysfunction and glutamate reuptake: effect of EAAT2 polymorphism in schizophrenia. *Neurosci. Lett.* 522, 151–155. <https://doi.org/10.1016/j.neulet.2012.06.030>.
- Spangaro, M., Bosia, M., Bechi, M., Buonocore, M., Cocchi, F., Guglielmino, C., Bianchi, L., Mastromatteo, A., Lorenzi, C., Cavallaro, R., 2018. Neurobiology of cognitive remediation in schizophrenia: effects of EAAT2 polymorphism. *Schizophr. Res.* 202, 106–110. <https://doi.org/10.1016/j.schres.2018.06.059>.
- Strassnig, M., Signorile, J., Gonzalez, C., Harvey, P.D., 2014. Physical performance and disability in schizophrenia. *Schizophr. Res. Cogn.* 1, 112–121. <https://doi.org/10.1016/j.schres.2014.06.002>.
- Tandon, R., Nasrallah, H.A., Keshavan, M.S., 2009. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. *Schizophr. Res.* 110, 1–23. <https://doi.org/10.1016/j.schres.2009.03.005>.
- Upthegrove, R., Khandaker, G.M., 2020. Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia. *Curr. Top. Behav. Neurosci.* 44, 49–66. https://doi.org/10.1007/7854_2018_88.
- Upthegrove, R., Manzanarez-Teson, N., Barnes, N.M., 2014. Cytokine function in medication-naïve first episode psychosis: a systematic review and meta-analysis. *Schizophr. Res.* 155, 101–108. <https://doi.org/10.1016/j.schres.2014.03.005>.
- Uranova, N.A., Vikhreva, O.V., Rakhmanova, V.I., Orlovskaya, D.D., 2020. Dystrophy of oligodendrocytes and adjacent microglia in prefrontal gray matter in schizophrenia. *Front. Psychol.* 11, 204. <https://doi.org/10.3389/fpsyg.2020.00204>.
- Verma, A., Moghaddam, B., 1996. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. *J. Neurosci.* 16, 373–379. <https://doi.org/10.1523/jneurosci.16-01-00373.1996>.
- Vita, A., De Peri, L., Deste, G., Sacchetti, E., 2012. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. *Transl. Psychiatry* 2, e190. <https://doi.org/10.1038/TP.2012.116>.
- Vita, A., Gaebel, W., Mucci, A., Sachs, G., Barlati, S., Giordano, G.M., Nibbio, G., Nordentoft, M., Wykes, T., Galderisi, S., 2022. European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia. *Eur. Psychiatry* 65, e57. <https://doi.org/10.1192/J.EURPSY.2022.2315>.
- Wang, Y., Qin, Z.H., 2010. Molecular and cellular mechanisms of excitotoxic neuronal death. *Apoptosis* 15, 1382–1402. <https://doi.org/10.1007/s10495-010-0481-0>.
- Wykes, T., Huddy, V., Cellard, C., McGurk, S.R., Czobor, P., 2011. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. *Am. J. Psychiatry* 168, 472–485. <https://doi.org/10.1176/APPI.AJP.2010.10060855>.
- Xu, Y., Cai, Z., Fang, C., Zheng, J., Shan, J., Yang, Y., 2022. Impact of aerobic exercise on cognitive function in patients with schizophrenia during daily care: a meta-analysis. *Psychiatry Res.* 312, 114560 <https://doi.org/10.1016/j.psychres.2022.114560>.
- Yaffe, K., Kanaya, A., Lindquist, K., Simonsick, E.M., Harris, T., Shorr, R.I., Tylavsky, F. A., Newman, A.B., 2004. The metabolic syndrome, inflammation, and risk of cognitive decline. *JAMA* 292, 2237–2242. <https://doi.org/10.1001/jama.292.18.2237>.
- Yamada, S., Takahashi, S., Malchow, B., Papazova, I., Stöcklein, S., Ertl-Wagner, B., Papazov, B., Kumpf, U., Wobrock, T., Keller-Varady, K., Hasan, A., Falkai, P., Wagner, E., Raabe, F.J., Keeser, D., 2022. Cognitive and functional deficits are associated with white matter abnormalities in two independent cohorts of patients with schizophrenia. *Eur. Arch. Psychiatry Clin. Neurosci.* 272, 957–969. <https://doi.org/10.1007/s00406-021-01363-8>.
- Zanardi, R., Spangaro, M., Attanasio, F., Sapienza, J., Martini, F., Fregna, L., Cavallaro, R., Colombo, C., 2022. Psychopharmacology. In: Cavallaro, R., Colombo, C. (Eds.), *Fundamentals of Psychiatry for Health Care Professionals*. Springer, p. 456. <https://doi.org/10.1007/978-3-031-07715-9>.
- Zhang, Y., Catts, V.S., Sheedy, D., McCrossin, T., Kril, J.J., Shannon Weickert, C., 2016. Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation. *Transl. Psychiatry* 6, e982. <https://doi.org/10.1038/TP.2016.238>.
- Zimmer, M., Duncan, A.V., Laitano, D., Ferreira, E.E., Belmonte-de-Abreu, P., 2007. A twelve-week randomized controlled study of the cognitive-behavioral integrated psychological therapy program: positive effect on the social functioning of schizophrenic patients. *Rev. Bras. Psiquiatr.* 29, 140–147. <https://doi.org/10.1590/S1516-44462006005000030>.